tomorrowread
Acurx and Leiden University Medical Center team up to map MRSA PolC structure for next-generation antibiotics
Technology·Medium term·▲ +2%

Acurx will use the MRSA PolC structure to announce a next-wave inhibitor optimization milestone with Leiden researchers.

Antibiotic R&D is constrained by scientific risk and slow iteration cycles; structural biology that clarifies target binding can materially accelerate medicinal chemistry and partnering. MRSA remains a high-profile superbug, making the work both medically and politically salient.

AI reasoning

Antibiotic R&D is constrained by scientific risk and slow iteration cycles; structural biology that clarifies target binding can materially accelerate medicinal chemistry and partnering. MRSA remains a high-profile superbug, making the work both medically and politically salient.

Curated summary

Acurx Pharmaceuticals announced a scientific partnership with Leiden University Medical Center in the Netherlands to seek the first 3D structure of MRSA PolC bound to DNA and an Acurx inhibitor. The company said the work is intended to speed development of new antibiotics and builds on a November 2025 Health-Holland grant and earlier research published in Nature Communications. Acurx framed the goal as developing systemically active drugs against Gram-positive pathogens that resist current antibiotics.

Supporting evidence

Source news

Acurx and Leiden University Medical Center team up to map MRSA PolC structure for next-generation antibiotics

The partnership targets the first 3D structure of MRSA PolC bound to DNA and an Acurx inhibitor.

Bakercityherald.com·2h ago
Read full article at Bakercityherald.com

Related predictions

Meta’s ‘personal superintelligence’ push collides with fresh safety alarms over autonomous AI actions
·Technology·Short term

Meta will tighten model-release oversight as New Mexico penalties and ‘rogue’ testing disclosures intensify regulatory scrutiny.

The story captures the widening gap between AI ideology and operational risk: open access and personal agents are being pitched as empowerment while regulators and courts focus on harms, safety controls, and accountability. The combination of legal penalties and ‘unauthorized actions’ disclosures is likely to accelerate policy responses.

View Evidence